Paul Leis, DO
Hospitalist · Manhasset, NYNPI 1871913830
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,665 of the $5,203 with a category attached, or 89.7%. It is spread thinly across 25 manufacturers, the largest accounting for just 16.8% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2020 at $1,760 and has fallen 76.5% since, to $414 in 2025. Among hospitalist clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 162 payments — averaging $32.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$876
- Abiomed$778
- Amgen$734
- AstraZeneca$297
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$286
- Boehringer Ingelheim$264
- plus $2K from 19 others
What the payments were for
- Consulting fees$1503%
- Food & beverage$4,66590%
- Education$3887%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 21 | $876 |
| Abiomed | 13 | $778 |
| Amgen | 30 | $734 |
| AstraZeneca | 15 | $297 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 10 | $286 |
| Boehringer Ingelheim | 9 | $264 |
| Abbott | 3 | $263 |
| Novartis | 12 | $243 |
| Johnson & Johnson | 9 | $206 |
| Astellas Pharma US Inc | 3 | $201 |
| Elucid Bioimaging Inc | 1 | $150 |
| Esperion Therapeutics, Inc. | 3 | $150 |
| Bayer | 5 | $104 |
| Kiniksa Pharmaceuticals International, PLC | 4 | $90 |
| Akcea Therapeutics, Inc. | 3 | $88 |
| Merck | 3 | $81 |
| Philips North America LLC | 4 | $78 |
| Alnylam Pharmaceuticals Inc. | 3 | $75 |
| Lantheus Medical Imaging, Inc. | 2 | $59 |
| Lexicon Pharmaceuticals, Inc. | 2 | $49 |
| Pfizer | 3 | $44 |
| Endotronix, Inc. | 1 | $31 |
| E.r. Squibb & Sons, L.L.C. | 1 | $20 |
| Medtronic | 1 | $19 |
| Nuwellis, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Impella$441
- GENERAL - THERAPIES$264
- Ensite Cardiac Mapping System$209
- PlaqueIQ$150
- NEXLIZET$125
- NEXLETOL$125
- EMBLEM MRI S-ICD$125
- RESONATE$122
- Repatha$105
- Watchman$103
How this compares
$5,203 in reported general payments places this provider in the 95th percentile of 1,860 hospitalist providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 111 | $78,557 |
| Repatha SureclickEvolocumab | 95 | $58,777 |
| JardianceEmpagliflozin | 13 | $21,161 |
| EntrestoSacubitril/Valsartan | 28 | $21,002 |
| Praluent PenAlirocumab | 11 | $5,372 |
| Rosuvastatin Calcium | 191 | $3,037 |
| Ezetimibe | 132 | $2,988 |
| Metoprolol Succinate | 220 | $2,901 |
| Valsartan | 73 | $2,120 |
| Atorvastatin Calcium | 139 | $1,352 |
| Amlodipine-ValsartanAmlodipine Besylate/Valsartan | 16 | $1,021 |
| Valsartan-HydrochlorothiazideValsartan/Hydrochlorothiazide | 21 | $836 |
| Amlodipine Besylate | 169 | $806 |
| Nebivolol Hcl | 15 | $659 |
| Nifedipine ErNifedipine | 24 | $470 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $44 | $78,557111 claims |
| Boehringer IngelheimJardiance | $264 | $21,16113 claims |
| NovartisEntresto | $243 | $21,00228 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,860 hospitalist providers in New York.
Other hospitalist in Manhasset
- Nelson Chan-HungRochester$445K
- Saquib RahimFlushing$239K
- Zainab Mogul-AshrafMiddletown$190K
- Salman AzimRochester$88K
- Usman SiddiquiNyack$70K
- Yair SapersteinNew York$43K
- Timothy TiutanNew York$42K
- Heather ZadeAlbany$37K
- Natasha VartakNew York$35K
- Sunil BhattNew York$25K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.